AEGiS-GMHC: TREATMENT BRIEFS: ddI Approved

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

TREATMENT BRIEFS: ddI Approved

Gay Men's Health Crisis Treatment Issues, Vol. 5, No. 8 - November 1991

FDA approval of ddI is ground-breaking in many areas: ddI is the first drug to be approved solely on the basis of T4 counts; the first drug to be approved for both adults and children at the same time, and the first anti-HIV drug since AZT's approval in 1987. Videx, ddI's brand-name, is for adult and pediatric patients with advanced HIV infection who are intolerant of AZT or have demonstrated deterioration on AZT. Since "advanced HIV," "intolerant," and "deterioration" are loosely defined, patients and their physicians will have freer reign over choosing and accessing this therapy. The price of ddI will be less than the price of AZT, costing approximately $1,745.00 per year, wholesale. The manufacturer of ddI, Bristol Meyers, deserves significant credit for agreeing to an expanded access program for ddI, which provided the drug free of charge to over 22,000 PWA's, and for pricing ddI, at a less expensive cost than other treatments such as AZT. For information regarding reimbursement, call Bristol Meyers's VIDEX HelpLine at (800) 788-0123, 8 am - 8 pm, M-F.

Copyright (c) 1991 - Gay Men's Health Crisis. Non-commercial reproduction encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com

9111
GM05805

Copyright © 1991 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .